- Primary research
- Open Access
Proteasome-mediated degradation antagonizes critical levels of the apoptosis-inducing C1D protein
© Rothbarth et al; licensee BioMed Central Ltd. 2002
- Received: 10 March 2002
- Accepted: 2 September 2002
- Published: 2 September 2002
The C1D gene is expressed in a broad spectrum of mammalian cells and tissues but its product induces apoptotic cell death when exceeding a critical level. Critical levels are achieved in a fraction of cells by transient transfection with EGFP-tagged C1D expression constructs. However, transfected cells expressing sub-critical levels of C1D(EGFP) escape apoptotic cell death by activation of a proteasome-mediated rescue mechanism. Inhibition of the proteasome-dependent degradation of the C1D(EGFP) protein results in a parallel increase of the intracellular C1D level and in the fraction of apoptotic cells.
- Apoptotic Cell Death
- Enhanced Green Fluorescent Protein
- Plasmid Copy
- Post Transfection
- Ehrlich Ascites Tumor Cell
The C1D gene encodes a conserved DNA-binding protein  which is expressed in all eukaryotic cells and tissues tested . However, the physiological level of this protein must be tightly regulated because additional ectopic expression induces apoptotic cell death . Previous studies showed that the C1D protein can serve as a DNA end-independent activator of DNA-PK  and that its overflow is paralleled by increased p21Cip1(Waf1) levels . Accordingly, the C1D protein represents a cryptic activator of apoptosis, and its over-expression could be applied to induce apoptosis in non-desired cells, e.g. in tumor cells. Accordingly, approaches resulting in increased levels of this protein are of interest. This study shows that the vector-based overflow of the C1D protein can be significantly enhanced by inhibition of the proteasome-dependent degradation system.
Threshold level for C1D-induced apoptosis
The complete disappearance of fluorecent cells at 120 hours post transfection is only partly due to cell death of those cells exhibiting the morphologies shown in Fig. 2 because the drop in the number of fluorescent cells is not accompanied by an adequate drop in the total number of cells (not shown). Accordingly, cells expressing subcritical levels escape apoptotic cell death because they appear to be capable to induce a rescue mechanism which prevents overcritical C1D(EGFP) levels. Obviously, this mechanism is fully induced at 120 hours post transfection (Fig. 1). At this time C1D(EGFP) degradation overrides expression of this protein resulting in normally growing cells devoid of fluorescence.
These results are best explained by a point-of-no-return mechanism in C1D-dependent apoptosis signalling. Overcritical C1D protein levels are expectedly achieved in those cells with an initially high number of plasmid copies per cell. In this case, the C1D(EGFP) threshold level is presumptively exceeded and apoptosis is inevitably induced while cells with a lower number of plasmid copies per cell expressing only subcritical C1D(EGFP) levels still remain capable to activate a C1D-directed elimination mechanism.
Identification of the rescue mechanism
The C1D portion of the fusion protein must be considered to comprise the decisive signal for the proteasome-mediated degradation because the level of ectopically expressed EGFP is only weakly increased in the presence of MG115, and MG115-induced degradation is also not a general characteristics of EGFP-tagged proteins. For instance, the level of the apoptosis-related ZIP-kinase-EGFP  is not significantly increased in the presence of the MG115 inhibitor (not shown).
Inhibition of proteasome-dependent proteolysis favours apoptotic cell death by increasing gene products considered to be involved in apoptosis signalling [5, 6]. Examples for apoptosis-related gene products upregulated by proteasome-specific inhibitors include p53 [7–10], p73 , p21Cip1(Waf1) [12, 13], p27Kip [12, 14], and caspases [15, 16]. Our results indicate that the C1D protein must be added to this list of factors.
Physiological levels of the C1D protein are apparently innoxious and rather essential for cell viability. However, a critical overexpression is not tolerated with the consequence of apoptotic cell death . Consistently, C1D expression is tightly regulated on the transcriptional and on the posttranscriptional level. The promoter activity is repressed by cis-acting sequences comprised in a LINE-1 upstream element , and proteasome-mediated degradation appears to avoid accidental protein levels. Consequently, a critical C1D(EGFP) level is only achieved in a relatively small fraction of cells suggestively transfected with a high number of plasmid copies per cell. In contrast, transfectants initially expressing subcritical levels of the cytotoxic protein have the capability to override the ectopical overexpression of the cytotoxic protein by activation of a proteasome-dependent mechanism which degrades C1D(EGFP). Consistently, inhibition of the latter process results in a shift towards higher yields of apoptotic cells. The concomitant inhibition of the degradation of other apoptosis-favouring proteins [7–16] may contribute to this higher yield of apoptotic cells.
Survival of tumor cells is in all or in part due to their inability to activate the programmed cell death . Accordingly, factors with the characteristics of C1D are of interest with respect to the elimination of nondesired cells, e.g. tumor cells. It is concluded that the yield of apoptotic cells is significantly increased by vector-dependent C1D expression in combination with inhibitors of the proteasome-dependent degradation of the C1D gene product.
EGFP fusion and expression constructs
The preparation of C1D(EGFP) expression constructs are described elsewhere in detail . Briefly, the PCR-amplified sequence encoding the murine C1D protein (X95591) was fused with the sequence encoding EGFP (Clontech) in the pBluescript KS+ vector (Stratagene). The fused C1D(EGFP) sequence was excised with suitable restrictases and recloned either in the CMV promoter-driven pcDNA3 vector (Invitrogen) or in the SV40 promoter-driven pJ3Ω vector . The sequence encoding the ZIP-kinase  was assembled from coding fragments present on ESTs (IMAG 457285, IMAG 386126) which were received from the 'Ressourcenzentrum im Deutschen Humangenomprojekt'. Fusion with the EGFP-encoding sequence and recloning in the pcDNA3 vector was performed as described for the C1D sequence. For controls the EGFP-encoding sequence was recloned in the pcDNA3 vector.
Cell cultures and transient transfections
Ehrlich ascites tumor (EAT) cells grown as described elsewhere in detail  were transfected with Qia-tip (Qiagen) purified plasmids by electroporation using the Biorad Gene Pulser II (cell density 107 per ml, electrode distance D = 4 mm, 366V / 950 μF). For detection of proteasome inhibitor effects the medium of exponentially growing transfected and non-transfected cells was supplemented with MG115 (benzyloxycarbonyl-leu-leu-norvalinal, Calbiochem) to obtain the final concentrations mentioned in the legends of Figures 4 and 5.
EAT cells were lysed in 2× sample buffer containing 5% β-mercapto ethanol at 95°C. Aliquots corresponding to a defined number of cells and prestained marker proteins were submitted to SDS polyacrylamide (12% w / v) gel electrophoresis. Gel lanes were electro-blotted to nitrocellulose membranes, blocked (PBS / 1% BSA), and probed with C1D antibodies preadsorbed at recombinant murine C1D protein . The second antibody was 125Iodine-labeled anti rabbit Ig (Amersham). Blots were exposed to Kodak X-Omat film and images were captured by means of an electronic camera (Herolab).
The Openlab imaging sytem (Improvision, Warwick, UK) was used to capture images. Cells were collected, washed with phosphate-buffered saline (PBS), counterstained with Hoechst 33342 (0.1 μg per ml), resuspended in Hanks' balanced salt solution (HBSS), mounted on glass slides and inspected by microscopy. The 'Measurements Module' was used to measure mean fluorescence intensities per cell in regions of interest (ROIs).
- Nehls P, Keck T, Greferath R, Spiess E, Glaser T, Rothbarth K, Stammer H, Werner D: cDNA cloning, recombinant expression and characterization of polypeptides with exceptional DNA affinity. Nucleic Acids Res. 1998, 26: 1160-1166. 10.1093/nar/26.5.1160.PubMed CentralView ArticlePubMedGoogle Scholar
- Rothbarth K, Spiess E, Juodka B, Yavuzer U, Nehls P, Stammer H, Werner D: Induction of apoptosis by over-expression of the DNA-binding and DNA-PK-activating protein C1D. J Cell Science. 1999, 112: 2223-2232.PubMedGoogle Scholar
- Yavuzer U, Smith GCM, Bliss T, Werner D, Jackson P: DNA end-independent activation of DNA-PK is mediated via association with the DNA-binding protein C1D. Genes and Development. 1998, 12: 2188-2199.PubMed CentralView ArticlePubMedGoogle Scholar
- Kawai T, Matsumoto M, Takeda K, Sanjo H, Akira S: ZIP Kinase, a novel serine / threonine kinase which mediates apoptosis. Mol Cell Biol. 1998, 18: 1642-1651.PubMed CentralView ArticlePubMedGoogle Scholar
- Shinohara K, Tomiok M, Nakano H, Tone S, Ito H, Kawashima S: Apoptosis induction resulting from proteasome inhibition. Biochem J. 1996, 317: 385-388.PubMed CentralView ArticlePubMedGoogle Scholar
- Drexler HC: Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci USA. 1997, 94: 855-860. 10.1073/pnas.94.3.855.PubMed CentralView ArticlePubMedGoogle Scholar
- Ichihara A, Tanaka K: Roles of proteasomes in cell growth. Mol Biol Rep. 1995, 21: 49-52.View ArticlePubMedGoogle Scholar
- Maki CG, Huibregtse JM, Howley PM: In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res. 1996, 56: 2649-54.PubMedGoogle Scholar
- Honda R, Tanaka H, Yasuda H: Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 1997, 420: 25-27. 10.1016/S0014-5793(97)01480-4.View ArticlePubMedGoogle Scholar
- Chang YC, Lee YS, Tejima T, Tanaka K, Omura S, Heintz NH, Mitsui Y, Magae J: mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway. Cell Growth Differ. 1998, 9: 79-84.PubMedGoogle Scholar
- Lee CW, La-Thangue NB: Promoter specificity and stability control of the p53-related protein p73. Oncogene. 1999, 18: 4171-4181. 10.1038/sj.onc.1202793.View ArticlePubMedGoogle Scholar
- Blagosklonny MV, Wu GS, Omura S, el Deiry WS: Proteasome-dependent regulation of p21WAF1/CIP1 expression. Biochem Biophys Res Commun. 1996, 14: 564-569. 10.1006/bbrc.1996.1546.View ArticleGoogle Scholar
- Cayrol C, Ducommun B: Interaction with cyclin-dependent kinases and PCNA modulates proteasome-dependent degradation of p21. Oncogene. 1998, 12: 2437-2444. 10.1038/sj.onc.1202189.View ArticleGoogle Scholar
- Han S, Park K, Kim HY, Lee MS, Kim HJ, Kim YD: Reduced expression of p27Kip1 protein is associated with poor clinical outcome of breast cancer patients treated with systemic chemotherapy and is linked to cell proliferation and differentiation. Breast Cancer Res Treat. 1999, 55: 161-167. 10.1023/A:1006258222233.View ArticlePubMedGoogle Scholar
- Chandra J, Niemer I, Gilbreath J, Kliche KO, Andreeff M, Freireich EJ, Keating M, McConkey DJ: Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes. Blood. 1998, 92: 4220-4229.PubMedGoogle Scholar
- Zhang XM, Lin H, Chen C, Chen BD: Inhibition of ubiquitin-proteasome pathway activates a caspase-3-like protease and induces Bcl-2 cleavage in human M-07e leukaemic cells. Biochem J. 1999, 15: 127-133. 10.1042/0264-6021:3400127.View ArticleGoogle Scholar
- Rothbarth K, Hunziker A, Stammer H, Werner D: Promoter of the gene encoding the 16 kDa DNA-binding and apoptosis-inducing C1D protein. Biochim Biophys Acta. 2001, 91536: 1-5.Google Scholar
- Donehower LA, Harvey M, Slagle BL, McArthur MI, Montgomery CA, Butel JS, Bradley A: Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature. 1992, 356: 215-221. 10.1038/356215a0.View ArticlePubMedGoogle Scholar
- Morgenstern JP, Land H: A series of mammalian expression vectors and characterisation of a reporter gene in stably and transiently transfected cells. Nucleic Acids Res. 1990, 18: 1068-PubMed CentralView ArticlePubMedGoogle Scholar
- Granzow C, Kopun M, Kroeber T: Riboflavin-mediated photosensitization of Vinca alkaloids distorts drug sensitivity assays. Cancer Res. 1995, 55: 4837-4843.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.